MILWAUKEE, May 5, 2020 /PRNewswire/ -- Ademi & O'Reilly,
LLP is investigating Portola (Nasdaq: PTLA) for possible
breaches of fiduciary duty and other violations of the law in
connection with the sale to Alexion.
Click here to learn how to join the action:
http://ademilaw.com/case/portola-pharmaceuticals-inc or call
Guri Ademi toll-free at
866-264-3995. There is no cost or obligation to you.
Ademi & O'Reilly, LLP alleges Portola's financial outlook is
improving and yet shareholders will receive only $18 per share in cash. The merger agreement
unreasonably limits competing bids for Portola by prohibiting
solicitation of further bids, and imposing a termination penalty if
Portola accepts a superior bid. Portola insiders will
receive millions of dollars as part of change of control
arrangements. We are investigating the conduct of Portola's board
of directors, and whether they are (i) fulfilling their fiduciary
duties to all shareholders, and (ii) obtaining a fair and
reasonable price for Portola.
If you own common stock in Portola and wish to obtain
additional information, please contact Guri
Ademi either at gademi@ademilaw.com or toll-free:
866-264-3995, or
http://ademilaw.com/case/portola-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts,
mergers, and individual shareholder rights throughout the country.
For more information, please feel free to call us. Attorney
advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi & O'Reilly, LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original
content:http://www.prnewswire.com/news-releases/shareholder-alert-ademi--oreilly-llp-investigates-whether-portola-pharmaceuticals-inc--has-obtained-a-fair-price-in-its-sale-to-alexion-pharmaceuticals-inc-301053034.html
SOURCE Ademi & O'Reilly, LLP